TMCI Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 2.24%, SMA50 -12.13%, SMA200 -57.59%). The stock’s 14-day RSI is 46.07 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -79.06% below its high and over 16.02% above its low. Average 10-day trading volume of 609.72 thousand shares is below the 3-month average of 835.56 thousand, indicating normal recent market interest.

Treace Medical Concepts, Inc. has 63.17 million shares outstanding. The public float is 47.24 million shares, elevated short interest at 6.64% of float. This equals 3.18 million shares. The short ratio is 8.01 days. Institutional investors hold 73.8% of the float. Insiders own 24.79%. Treace John T. holds 7.16 million shares, TREACE JAMES T has 1.22 million shares and TIMBIE THOMAS E has 1.15 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Treace Medical Concepts, Inc. generated EPS of -$0.79 over the past year. Five-year average earnings growth is -56.4%. Wall Street analysts project EPS growth of 3.03% annually over the next five years. The latest quarter delivered EPS of -$0.28. The next quarter is forecast at -$0.15. Next year's EPS is expected at $21.14. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 8 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $8.00 to $4.00. The high target offers 188.81% upside. The low target suggests 44.4% downside. The mean target is $5.88. This offers 112.27% upside. Treace Medical Concepts, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 08, 2026, missed forecasts by -9.68%. The prior quarter beat by -21.0%. Over the last six quarters, Apple has recorded several small beats. These include -75.0% in February 27, 2025.

Treace Medical Concepts, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.49. This means the shares are trading below this model’s fair value.

Treace Medical Concepts, Inc. (NASDAQ:TMCI) closed at $2.77 USD, gaining $0.24 (9.49%) from the previous close of $2.53. The stock is currently mid-range between its 52-week high and low $1.17 and $7.78. With a market capitalization of about $179.70 million, Treace Medical Concepts, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.11). Key stats such as the average daily volume over the past year has been around 833.05 thousand shares, in line with its 52-week average. Headquartered in Ponte Vedra, FL, Treace Medical Concepts, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO John T. Treace, the company employs approximately 477 people and listed since April 23, 2021. Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States.

Treace Medical Concepts, Inc. trades at a P/E ratio of -2.97, slightly below the S&P 500 average, with a price-to-sales ratio of 0.88 and a price-to-book ratio of 2.35 suggesting the stock is closer to book value. The P/FCF stands at -7.0, also below market averages.

Treace Medical Concepts, Inc. (NASDAQ:TMCI) shares are flat 6.12% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Treace Medical Concepts, Inc. trading at a premium to the broader market with a P/E of -2.97. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $15.92, suggesting 474.73% upside. Our AI forecast model points to short-term strength (3.25% over two weeks), a medium-term fall (-22.02% over three months), and a longer-term loss (-97.11% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Treace Medical Concepts, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.25%, with price expected at $2.86 by May 28, 2026, within a range of $2.68 to $3.04 3-Month Outlook: Projected fall of -22.02%, reaching $2.16 by August 12, 2026, with a range of $1.89 to $2.40. 1-Year Outlook: Projected loss of -97.11%, with price at $0.08 by May 14, 2027, within a range of $0.00 to $0.00.